Bridging the Gap between Diabetes, Heart Failure and Vascular Risk – From prevention to treatment with SGLT2i: Applying new evidence to clinical practice

Click here to view in chapters format

Learning Objectives

• Describe the role of heart failure in people with diabetes and vascular disease
• Discuss the clinical trial data on SGLT2i in the treatment of established heart failure
• Apply a new clinical algorithm to use SGLT2i in patients with vascular disease and heart failure

Agenda

Faculty

Dr. Mohammed Al-Omran
MD, MSc, FRCSC
CO-CHAIR
Head of Vascular Surgery,
St. Michael’s Hospital
Professor of Surgery, and, Pharmacology
and Toxicology, University of Toronto,
Toronto, ON

Professor Subodh Verma
MD, PhD, FRCSC, FAHA
CO-CHAIR
Cardiac Surgeon, St. Michael’s Hospital;
Professor of Surgery and Pharmacology &
Toxicology, University of Toronto;
Canada Research Chair in Cardiovascular
Surgery, Toronto, ON

Professor Lawrence A. Leiter
MD, FRCPC, FACP, FACE, FAHA, FACC
CO-CHAIR
Endocrinologist,
St. Michael’s Hospital;
Professor of Medicine and Nutritional
Sciences, University of Toronto,
Toronto, ON

Dr. Michael A. McDonald
MD, FRCPC
Cardiologist, Peter Munk Cardiac Centre
Assistant Professor of Medicine,
University of Toronto,
Toronto, ON

Professor John J. V. McMurray
MB ChB (Hons), MD, FRCP, FESC, FACC,
FAHA, FRSE, FMedSci
Professor of Medical Cardiology, Deputy
Director, Honorary Consultant Cardiologist,
BHF Cardiovascular Research Centre, Institute
of Cardiovascular and Medical Sciences,
University of Glasgow,
Glasgow, UK

Dr. Eileen O’Meara
MD, FRCPC
Cardiologist, Montreal Heart Institute;
Associate Professor of Medicine,
Université de Montréal,
Montréal, QC

Dr. Shelley Zieroth
MD, FCCS, FRCPC
Cardiologist, St. Boniface Hospital
Associate Professor,
University of Manitoba
President, Canadian Heart Failure Society
Winnipeg, MB

This event is an accredited group learning activity (section 1) as defined by the maintenance of certification program with the Royal College of Physicians and Surgeons of Canada. This activity has been approved by the Canadian Society for Vascular Surgery.